

CL Healthcare Group Success Stories

1/7


- *For Patients and Doctors: Meritocracy synergetic choice within basket therapies of generic and patented prescription drugs manufactured under license or marketed under sales fostering contract*
- 9 years collaboration with **Roche** — both in contractual outsourcing of anti-invectives and in-licensed manufacturing for Parkinson disease, AH, HF, CAD. **Each contacted product is the leader in its class**
- 6 years collaboration with **Pfizer** — marketing agreement for the entire cardiovascular portfolio (incl. Lipitor) and schizophrenia
- Attractive partner of choice for marketing and in-licensing production for Big Pharma and Biotech multinationals
- Six eloquent illustrations of Commercial League group's mastery in generating sustainable pharmaceutical sales in the key therapeutical areas (CV, CNS and Respiratory) follow:

February 2010

CL Healthcare Group Success Stories

2/7

CL Healthcare Group / Pfizer anti-hypertension cooperation: up and downs in the Accupro® case study




May 2010

Source: CL Data Bank

CL Healthcare Group Success Stories

3/7

**CL Healthcare Group / Roche cooperation
in heart failure treatment: the Dilatrend® EVERGREENING case study**




May 2010

Source: CL Data Bank

CL Healthcare Group Success Stories

4/7

**CL Healthcare Group / Roche anti-Parkinson cooperation:
the Madopar® case study in a conservative market**




May 2010

Source: CL Data Bank

CL Healthcare Group Success Stories

5/7

CL Healthcare Group / AstraZeneca cooperation: the Seroquel® case study



For less than a year sales were doubled and Seroquel turned into Number One product for Schizophrenia and Bipolar Disorder


May 2010

Source: CL Data Bank

CL Healthcare Group Success Stories

6/7

CL Healthcare Group / AstraZeneca cooperation: the Symbicort® electrifying success in Respiratory



For 6 months sales sky-rocketed and Symbicort [after the terrific re-launch campaign] turned into main therapeutic choice for asthma and COPD


May 2010

Source: CL Data Bank

CL Healthcare Group Success Stories 7/7

Insuman[®] & Lantus[®] (2005-2006)

Diabetes Campaign for sanofi~aventis




Fast penetration in the conservative insulin market dominated for years by 80% MS player

The fastest growing player in terms of new patients recruitment: over 70% of new patients

For less than one year three digit growth for sanofi~aventis

Facilitated launch for Lantus



May 2010

Source: CL Data Bank